Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?

Journal of Clinical Oncology

Volumn 22, Issue 10, 2004, Pages 1797-1806

  Gill, Sharlene ^b   Loprinzi, Charles L ^a   Sargent, Daniel J ^b   Thomé, Stephan D ^b   Alberts, Steven R ^b   Haller, Daniel G ^b   Benedetti, Jacqueline ^b   Francini, Guido ^b   Shepherd, Lois E ^b   Seitz, Jean Francois ^b   Labianca, Roberto ^b   Chen, Wei ^b   Cha, Stephen S ^b   Heldebrant, Michael P ^b   Goldberg, Richard M ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; ANTINEOPLASTIC AGENT;

AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; COLON TUMOR; DISEASE FREE SURVIVAL; FEMALE; MALE; MEDICAL RECORD; META ANALYSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL; TUMOR RECURRENCE; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEVAMISOLE; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES;

EID: 2542563257     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.09.059     Document Type: Article

References (52)

1. SEER Cancer Statistics Review 1973-1999. National Cancer Institute: Bethesda, MD. http://seer.cancer.gov/csr/1973_1999
2. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
3. Eisenberg B, Decosse JJ, Harford E, et al: Carcinoma of the colon and rectum: The natural history reviewed in 1704 patients. Cancer 49:1131-1134, 1982
4. Macdonald JS: Adjuvant therapy for colon cancer. CA Cancer J Clin 49:202-219, 1999
5. Elsaleh H, Joseph D, Grieu F, et al: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745-1750, 2000
6. Leighl N, Gattellari M, Butow P, et al: Discussing adjuvant cancer therapy. J Clin Oncol 19:1768-1778, 2001
7. Degner LF, Kristjanson LJ, Bowman D, et al: Information needs and decisional preferences in women with breast cancer. JAMA 277:1485-1492, 1997
8. Davison BJ, Degner LF. Morgan TR: Information and decision-making preferences of men with prostate cancer. Oncol Nurs Forum 22:1401-1408, 1995
9. Cassileth BR, Zupkis RV, Suttan-Smith K, et al: Information and participation preferences among cancer patients. Ann Intern Med 92:832-836, 1980
10. Ravdin PM, Siminoff IA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998
11. Sutherland HJ, Llewellyn-Thomas HA, Lockwood GA, et al: Cancer patients: Their desire for information and participation in treatment decisions. J R Soc Med 82:260-263, 1989
12. Loprinzi CL, Ravdin PM, de Laurentiis M, et al: Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J Clin Oncol 12:1422-1426, 1994
13. Loprinzi CL, Thome SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19:972-979, 2001
14. Rajagopal S, Goodman PJ, Tannock IF: Adjuvant chemotherapy for breast cancer: Discordance between physicians' perception of benefit and the results of clinical trials. J Clin Oncol 12:1296-1304, 1994
15. Siminoff LA, Fetting JH, Abeloff MD: Doctor-patient communication about breast cancer adjuvant therapy. J Clin Oncol 7:1192-1200, 1989
16. Mackillop WJ, Stewart WE, Ginsburg AD, et al: Cancer patients' perceptions of their disease and its treatment. Br J Cancer 58:355-358, 1988
17. Thome SD, Loprinzi CL, Heldebrant MP: Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas. Mayo Clin Proc 77:913-917, 2002
18. Landro L: Going Online to Make Life-and-Death Decisions. The Wall Street Journal, 2002, p. D1
19. Sonpavde G: Communicating the Value of Adjuvant Chemotherapy. J Clin Oncol 21:948-949, 2003
20. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
21. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447-1456, 1989
22. O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300, 1998
23. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
24. Francini G, Petrioli R, Lorenzini L, et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106:899-906, 1994
25. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-944, 1995
26. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Cox D: Regression models and life-tables. J R Stat Soc B 34:187-202, 1972
28. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
29. Little RJ, Rubin D: Statistical analysis with missing data. John Wiley and Sons, Inc. New York, NY, 2002
30. Raghunathan TE, Solenberger PW, Van Hoewyk J: IVEware: Imputation and variance estimation software. Institute for Social Research. University of Michigan, Ann Arbor, MI, 1998
31. Raghunathan TE, et al: A Multivariate Technique for Multiplying Imputing Missing Values Using a Sequence of Regression Models. Surv Methodol 27:85-95, 2001
32. Van Houwelingen JC, Le Cessie S: Predictive value of statistical models. Stat Med 9:1303-1325, 1990
33. Harrell FE, Lee KL, Mark DB: Tutorial in biostatistics multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
34. Chapuis PH, Dent OF, Fisher R, et al: A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 72:698-702, 1985
35. Cohen AM, Tremiterra S, Candela F, et al: Prognosis of node-positive colon cancer. Cancer 67:1859-1861, 1991
36. Iwashyna TJ, Lamont EB: Effectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 20:3992-3998, 2002
37. Wolmark N, Fisher B, Wieand HS, et al: The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199:375-382, 1984
38. Wolmark N, Wieand HS, Rockette HE, et al: The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 198:743-752, 1983
39. Steinberg SM, Barkin JS, Kaplan RS, et al: Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 57:1866-1870, 1986
40. Witzig TE, Loprinzi CL, Gancheroff NJ, et al: DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68:879-888, 1991
41. Le Voyer TE, Sigurdson ER, Hanlon AL, et al: Colon cancer survival is associated with increasing number of lymph nodes removed-A secondary analysis of intergroup trial INT-0089. J Clin Oncol 21:2912-2919, 2003
42. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241-250, 2003
43. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1195-1206, 2001
44. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69-77, 2000
45. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. N Engl J Med 349:247-257, 2003
46. Kim H, Jen J, Vogelstein B, et al: Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145:148-156, 1994
47. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
48. Halling KC, French AJ, McDonnell SK, et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295-1303, 1999
49. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17:1356-1363, 1999
50. Mamounas E, Wieand S, Wolmark H, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349-1355, 1999
51. Buyse M, Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28:20-24, 2001 (1 suppl 1)
52. Schrag D, Rifas-Shiman S, Saltz L, et al: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999-4005, 2002